SciELO - Scientific Electronic Library Online

 
vol.20 issue2Direct costs of breast cancer care in ColombiaCharacteristics of 130 patients who underwent gastrectomy for gastric cancer in the Instituto de Cancerología-Clínica Las Américas Medellín author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Colombiana de Cancerología

Print version ISSN 0123-9015

Abstract

GAMBOA, Oscar  and  MURILLO, Raúl. Estimate of the economic burden of pre-neoplastic lesions and cervical cancer in Colombia. Implications for HPV vaccination. rev.colomb.cancerol. [online]. 2016, vol.20, n.2, pp.61-72. ISSN 0123-9015.  http://dx.doi.org/10.1016/j.rccan.2016.02.004.

Objective: To estimate the economic burden cervical neoplastic disease in Colombia and the effects of its prevention. Methods: The incidence was calculated from a Markov model on the natural history of human papillomavirus (HPV) infection. Direct costs were estimated, in Colombian Pesos (COP), from cost-generating events identified in national and international guides. The monetary value of the procedures was based on current tariff manuals (ISS 2001 with a 30% adjustment and mandatory insurance (SOAT). The frequencies of use were defined by expert consensus. Screening program (cytology) and vaccination (HPV) costs were included. Results: The expected cases per year for IFRS (NIC) 1 (International Financial Reporting Standards), IFRS 2-3 and cancer were 177,317, 46,911, and 5,110, respectively. The cost of cytology was COP$19,070 (D 9.80) and each vaccine dose cost COP$23,700 (D 10.00). Screening represented the highest cost in the control of the disease (COP$126.933 million; D 38.5 million). The vaccine generated an additional cost of COP$11.977 million (D 3.5 million) and a saving of COP$15.969 million (D 4.8 million). This latter started 20 years after introducing the strategy. To reduce the cost of the vaccination contributes to a saving and to decrease the cost of screening shortens its start-up time. Conclusions: Vaccination against HPV reduces the costs of controlling uterine cervical cancer, but it requires a sustained investment for a long period of time. The reduction in the vaccine and screening costs would bring significant economic benefits, where the new, alternative technologies could play an important role.

Keywords : Uterine cervical; cancer; Mass screening; Costs and cost analysis; Vaccine against; human papillomavirus.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )